UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
von Paolo Palmigiano
6 von 6 Insights
Arbitration for life sciences companies
von mehreren Autoren
Legal advice privilege: where are we now?
von Georgina Jones
Brexit and MDR readiness for overseas medical devices manufacturers: where should you locate your sales operations in Europe?
von Alison Dennis
Territorial licensing: "start at the end before you begin"
von Colin McCall und Justyna Ostrowska
A missed chance
von Dr. Anja Lunze, LL.M. und Verena Bertram
Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
An exploration of patent pools, R&D and current initiatives.
von Dr. Anja Lunze, LL.M. und Dr. Jan Phillip Rektorschek
2 von 6 Insights
Termination, force majeure and frustration – international perspectives on the life sciences sector
von mehreren Autoren
COVID-19 and life sciences M&A
von mehreren Autoren